Potential Therapeutic Methods in Reproductive Aging
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: 23 August 2024 | Viewed by 1267
Special Issue Editor
Special Issue Information
Dear Colleagues,
Reproductive aging is a natural process that occurs in all women, eventually leading to fertility reduction and menopause. In recent decades, women’s life expectancy has been prolonged by as much as 30 years, but the onset of menopause has only been pushed back by apporximately 3–4 years. This means that a woman may spend a large period of her later life in poor health. In additon, ovarian aging remains a difficult problem in infertility treatment. In this respect, targeting ovarian longevity is very improatnt in terms of delayng the on-set of menopause, improving fertility, and further improving the health of women. For this reason, interest in the field of ovarian longevity, including ovarian rejuvernation, has increased in recent years. As a consequence, many reserarchers have conducted studies to overcome and rejuvenate ovarian aging. Such studies included the improvement of ovarian microenvironment through the stimulation of ovarian angiogenesis and the reduction of ovarian oxidative stress using pharmacological strategies; the activation of dormant primordial follicles and ovarian stem cells through the PI3K/PTEN/AKT/FOXO3 signaling pathway; and the improvement of ovarian function using various stem cells, such as bone marrow-derived stem cells, umbilical cord mesenchymal stem cells, and platelet-rich plasma. Recently, some promising outcomes have been introduced as potential therapeutic methods in reproductive aging. This Special Issue intends to summarize the state of the art, the latest findings published in the the field of ovarian longeivity and ovarian rejuvernation, as well as elucidate future directions.
- Stem cells as potential therapeutics in reproducitve agiung
- Antioxidants as potential therapeutics in reproducitve agiung
- Angiogenic factors as potential therapeutics in reproducitve agiung
- Activartors of dormant promordial follicle and ovarian stem cells as potential therapeutics in reproducitve agiung
- Cryopreservation of oocytes and ovaian tissues as potential therapeutics in reproducitve agiung
Dr. Bosun Joo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ovarian aging
- menopause
- infertility
- ovarian longevity/rejuvernation
- angiogenesis
- antioxidant
- stem cells
- platelet-rich plasma
